Figure 1. Absolute Standardized Mean Differences of Baseline Characteristics Between SGLT2i and DPP4i Groups Before and After Propensity Score Matching in the Overall Study Cohort.

Baseline characteristics were measured in the year before and at the index date (ie, the date of newly stable SGLT2i or DPP4i use in the study period). History of any cardiovascular disease (CVD) was determined from inpatient, outpatient, or emergency department medical records. A standardized mean difference greater than 0.1 indicates a significant between-group difference in the patient baseline characteristic. aDCSI indicates adapted Diabetes Complications Severity Index; AMI, acute myocardial infarction; CHD, coronary heart disease; DPP4is, dipeptidyl peptidase 4 inhibitors; GLA, glucose-lowering agent; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA_1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RAAS, renin-angiotensin-aldosterone system; SGLT2is, sodium-glucose cotransporter 2 inhibitors; TIA, transient ischemic attack; and TZD, thiazolidinedione.